Clinical Trial Update: A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating BL-M07D1 alone and in combination with Pertuzumab or Pertuzumab plus Docetaxel for unresectable locally advanced or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BL-M07D1
• DOCETAXEL (DOCETAXEL)
• Pertuzumab (pertuzumab)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING